Title: Association of *IRS1* (Gly972Arg) and *IRS2* (Gly1057Asp) genes polymorphisms with OSA and NAFLD in Asian Indians.

Author (s): *Surya Prakash Bhatt, PhD¹; Randeep Guleria, DM¹

Institute: ¹Department of Pulmonary Medicine and Sleep Disorders, All India Institute of Medical Sciences, New Delhi, India

Address for correspondence and reprint request to:

* Dr. Surya Prakash Bhatt

Senior Research Scientist

Department of Pulmonary Medicine and Sleep Disorders

All India Institute of Medical Sciences, New Delhi, India 110029

Contact: 011-26593676, E- mail: suryabhat@gmail.com

Abstract

Aim and Objective: The aim of the study was to investigate the relationships between insulin receptor substrate (*IRS*) 1 (Gly972Arg) and *IRS2* (Gly1057Asp) genes with obstructive sleep apnea (OSA) and non-alcoholic fatty liver disease (NAFLD) in Asian Indians.

Method: A total of 410 overweight/obese subjects (130 with OSA with NAFLD, 100 with OSA without NAFLD, 95 without OSA and with NAFLD and 85 without OSA and without NAFLD) were recruited. Degree of NAFLD was based on liver ultrasound and of OSA on overnight polysomnography.

Result: In *IRS1* gene, the genotype frequency (%) of Arg/Arg was significantly higher in NAFLD and OSA subjects. In addition, Gly/Arg genotype of *IRS1* gene was associated with significantly higher body mass index, fat mass, %body fat, triglycerides, cholesterol, alkaline phosphate, aspartate transaminase, fasting insulin and HOMA-IR levels in OSA and NAFLD subjects. No significant difference in genotype frequencies of *IRS2* was observed between four groups. Further we found that subjects carrying *IRS1* Gly/Arg (OR 4.49, 95% C.I. 1.06-12.52, p=0.002) genotype possess a much higher risk of OSA and NAFLD compared to *IRS2* Gly/Asp (OR 1.01, 95% C.I. 0.8-2.56, p=0.05).

Conclusion: We concluded that Asian Indian subject carrying the allele Gly972Arg polymorphism of *IRS1* is predisposed to develop OSA and NAFLD.

Keywords: Insulin receptor substrate, Obstructive sleep apnea, non alcoholic fatty liver disease, insulin resistance, obesity, Asian Indians

Introduction

Obstructive sleep apnea (OSA) is a common sleep problem in which complete airway obstruction, caused by pharyngeal collapse during sleeping time. The global prevalence in general populations is 9-38% (1, 2). In Indian studies, the prevalence of OSA is 4.4-13.7% (2, 3). In addition, OSA in Indian males varies from 4.4-19.7% and in females, it is between 2.5- 7.4% from the previous studies (2, 3). The prevalence of OSA also varies depending on the diagnostic criteria used and the age and sex of the population.

Non-alcoholic fatty liver disease (NAFLD) has a broad spectrum from fatty infiltration to severe fibrosis, cirrhosis, and hepatocellular carcinoma. Global prevalence of NAFLD is 25.24% with higher prevalence in the Middle East and South America and lower in Africa (4). In our previous study, we reported that the prevalence of NAFLD is 24.5-32.2% (5) and the primary risk factors for NAFLD are obesity, type 2 diabetes mellitus (T2DM), dyslipidemia, and insulin resistance.

Clinical finding showed that OSA has been associated with NAFLD. Recent metanalysis has been reported that OSA was independently associated with NAFLD in terms of liver enzymes and histological alterations (6). OSA causes accumulation of fatty acids in the liver as a result of nocturnal hypoxia, insulin resistance, metabolic syndrome, dyslipidemia, hypertension, oxidative stress and systemic inflammation. Another study has been indicated that nocturnal hypoxia causes NAFLD development and progression (7). However, nocturnal hypoxia is correlated with development and progression of NAFLD in OSA patients.

Insulin receptor is a hetero tetramer consisting of alpha (α) and beta (β) dimers. The α -subunit consisting of the ligand-binding site, while the β -subunit consists of a ligand-activated tyrosine kinase. On ligand binding, when tyrosine is phosphorylated, the insulin receptor gets converted into two intracellular substrates, insulin receptor substrate (IRS)-1 and insulin receptor substrate (IRS)-2. The gene for *IRS1* is located on chromosome 2q36 and encodes a 1,242-amino acid protein. The most common polymorphism in the *IRS1* gene (Gly972Arg), was reported to be associated with OSA (8) and NAFLD (9). The *IRS2* gene is located on chromosome 13q34 and encodes a protein of 1,354 amino acids. Moreover, the common polymorphism Gly1057Asp in the *IRS2* gene has also been reported to influence the susceptibility to insulin resistance and T2DM in polycystic ovary syndrome women (10). Till date, no studies have been investigated the association of *IRS1* and *IRS2* gene with OSA and NAFLD in Asian Indians.

We hypothesized that the *IRS1* (Gly972Arg) and *IRS2* (Gly1057Asp) genes may influence insulin resistance and are associated with risk of OSA and NAFLD in overweight non-diabetic Asian Indians. The aim of the present study was to investigate the relationships between *IRS1* and *IRS2* gene polymorphisms with OSA and NAFLD in Asian Indians.

Methodology

Subjects

A total of 410 overweight/ obese subjects [body mass index (BMI>23kg/m²)] with age from 20 to 60 years were evaluated from Outpatients Department of Pulmonary Medicine and Sleep Disorders Clinic at All India Institute of Medical Sciences (AIIMS), New Delhi, India between July 2012 to July 2017. Out of 410 subjects, 130 with OSA with NAFLD (group 1), 100 with OSA without NAFLD (group 2), 95 without OSA and with NAFLD (group 3) and 85 without OSA and without NAFLD (group 4) subjects have been recruited. The study was approved by the Institutional Ethics Committee of AIIMS, New Delhi, India. All experiments were performed in accordance with relevant guidelines and regulations. Written informed consent was obtained from all participants. Subjects with known T2DM, cardiovascular disease, other liver diseases, severe chronic obstructive pulmonary disease/ advanced lung disease with mechanical upper airway obstruction, severe organ damage, human immunodeficiency virus infection, pregnancy, and lactation, or with any pro-inflammatory state were excluded from the study.

Clinical, anthropometric and biochemical investigations

Blood pressure was measured over the right arm in sitting position after five-minute rest. Measurement of weight, height, body mass index, waist circumference (WC), hip circumference (HC), mid-thigh circumference (MTC) and skinfold thickness at 6 sites (triceps, biceps, anterior axillary, suprailiac, subscapular and lateral thoracic) were measured according to the methods adopted in the previous study (11). Determinations for fasting blood sugar (FBS), total cholesterol (TC), serum triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were done as previously described (12). Fasting insulin levels were measured by chemiluminescence (inter-assay CV 4.3%) using a Siemens Immulite 2000 (Siemens Healthcare). Hyperinsulinemia was defined by values in the highest quartile (13). The value of Homoeostasis Model Assessment of insulin resistance (HOMA-IR) was calculated as: fasting insulin (IU/ml) × fasting glucose (mmol/l)/22.5 (14).

Ultrasound imaging

All subjects were assessed by a liver ultrasound using 3.5MHz curvilinear probe (Siemens-G 60 S 2004, Germany). For this entire study ultrasound was done by a single radiologist. The definition of fatty liver was based on a comparative assessment of image brightness relative to the kidneys, in line with previously reported diagnostic criteria (15).

Overnight Polysomnography

All patients were called for the sleep study at 8.00 pm and were attached to Alice 3 infant and adult computerized polysomnography (PSG) system using the various leads and devices through standard gold cup electrodes (16). Overnight PSG was recorded according to standard protocols (17). Diagnosis of OSA was made on the basis of international

classification of sleep disorders (ASDA diagnostic classification steering committee). Breathing event was defined according to the commonly used clinical criteria published by American Academy of Sleep Medicine Task Force (16). PSG was conducted in a single sleep laboratory and analysis was done by a single expert.

Genetic Investigations

Genomic deoxyribonucleic acid (DNA) was extracted from whole blood using the QIAamp DNA extraction kit (Qiagen, Hilden, Germany) and stored at -20°C for the further experiments. The mean concentration of the samples was 80 to 90 ng/mL. Genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Its concentration and quality were then measured in a Nanodrop (Thermo Scientific, Waltham, MA, USA). DNA amplification and RFLP of the *IRS1* (Gly972Arg) and *IRS2* (Gly1057Asp) genes were performed by previously reported studies (18, 19). In this study, 60 samples has been confirmed for each polymorphism using DNA sequencing analysis.

Statistical Analysis

Data was entered in an Excel spreadsheet (Microsoft Corp, Washington, USA). The distribution of clinical, biochemical, anthropometric and body composition parameters were confirmed to approximate normality. Categorical data was analyzed by Chi-squared test, with Fisher correction when appropriate, and expressed as absolute number (%). Continuous variables were expressed as the mean $\pm$ standard deviation to summarize the variables. All continuous values were performed using the Z score method. The influence of the groups (1vs2, 1 vs3, 1vs 4, 2vs3 and 2vs4) was estimated by the Analysis of Covariance (ANCOVA) test with multiple comparisons. Pearson's correlation coefficient and significance of 'r' were used to compare the inflammatory marker levels and clinical parameters.

In order to determine if observed allele frequency was in conformity with the expected frequency (Hardy Weinberg equilibrium), chi-square analysis was done. Between-group differences in proportions of alleles or genotypes were compared using Chi-square test and a two-tailed Fisher's exact test. The influence of the genotype on the clinical biochemical, anthropometric and body composition parameters was estimated by ANOVA. Logistic regression analyses were carried out to identify the differences in genotypic frequencies and interaction of two SNPs between the groups. Bonferroni corrections for multiple comparisons were performed. The odds ratio (OR) and 95% confidence interval were used as a measure of strength for the association between *IRS1* (Gly972Arg) and *IRS2* (Gly1057Asp) genotypic combinations with the disease. A p-value <0.05 was considered as significant.

Results

Clinical, body composition, anthropometry and biochemical profiles

Clinical, body composition, anthropometry and biochemical profiles and detailed multi variable comparison (group 1vs2, 1 vs3, 1vs 4, 2vs3, 2vs4 and 3vs4) are presented in table 1, 2 and 3. It was observed that the mean values of blood pressure

(systolic and diastolic) ($p < 0.05$), BMI ($p = 0.003$), fat mass ($p = 0.02$), fat-free mass ($p = 0.002$) and %body fat ($p = 0.002$) was significantly higher in OSA with NAFLD group as compared to other groups.

Mean values of WC ($p = 0.001$), HC ($p = 0.003$), MTC ($p = 0.005$), neck circumference ($p = 0.0004$), suprailiac ($p = 0.02$), lateral thoracic ($p = 0.02$) and thigh ($p = 0.05$) was significantly higher in OSA with NAFLD group as compared to other groups.

The values of FBS ($p = 0.004$), serum TG ($p = 0.02$), TC ($p = 0.02$), HDL ($p = 0.005$), LDL ($p = 0.002$), AST ($p = 0.01$), ALT ($p = 0.03$), ALP ($p = 0.05$), fasting Insulin ($p = 0.001$) and HOMA-IR ($p = 0.001$) were significantly increased in OSA with NAFLD group.

Genotype distribution of IRS1 (Gly972Arg) and IRS2 (Gly1057Asp) genes

The group wise genotypic frequencies of *IRS1* (Gly972Arg) SNP are presented in table 4. Overall, 78.75% of subjects were *Gly/Gly* homozygous, 15.83% were *Gly/Arg* heterozygous, and 5.42% were *Arg/Arg* homozygous. Higher frequency of *Arg/Arg* genotype of *IRS1* gene was obtained in OSA and NAFLD ($p = 0.05$). The deviation from Hardy-Weinberg equilibrium among OSA and NAFLD patients for *IRS1* (Gly972Arg) ($p = 0.001$) indicated significant association between this SNP and the presence of OSA and NAFLD. The overall genotypic frequency of *IRS2* (Gly1057Asp) was 86.66% of subjects were *Gly/Gly* homozygous, 10.42% were *Gly/Asp* heterozygous, and 2.92% were *Asp/Asp* homozygous (table 4). The *IRS2* (Gly1057Asp) genotype frequencies did not follow Hardy Weinberg Equilibrium (chi value=10.5).

Multivariate logistic regression

Multivariate logistic regression analyses showed the carriers of homozygous *IRS1* Arg had an increased risk of OSA and NAFLD after adjusting for age, body mass index, fat mass, % body fat, FBG, TG, TC, and fasting insulin (OR 4.49, 95% C.I. 1.06-12.52, $p = 0.002$) (Table 4).

Comparision of IRS 1 and IRS-2 genotypes with clinical pheynotypes

Association of *IRS1* and *IRS-2* gene polymorphisms with clinical, body composition, anthropometric and biochemical parameters is shown in table 5 and 6. In OSA and NAFLD group, BMI, fat mass, % body fat, FBG, serum TG, TC, ALT, AST, fasting insulin and HOMA-IR levels were significantly increased in *Gly/Arg* genotype as compared to *Gly/Gly* genotype (figure 1). In OSA without NAFLD group, only BMI ($p = 0.01$) was significantly increased in *Gly/Arg* genotype (supplementary table 1). In group 3 and group 4, we did not find any significant association between the genotypes. *IRS2* gene polymorphism did not find any significant association between all the groups (supplementary table 2).

Discussion

This is the first study to investigate the relationships between *IRS1* and *IRS2* gene polymorphisms with OSA and NAFLD in Asian Indians. In this case control study, we showed that clinical, body composition and metabolic parameters were significantly higher in OSA and NAFLD subjects. Further, this study indicated that the frequency of Arg allele

of Gly972Arg polymorphisms of *IRS1* gene is significantly increased in OSA and NAFLD. Importantly, *IRS1* polymorphism is significant genetic determinant for insulin resistance and obesity in OSA and NAFLD. Indeed, subjects carrying *IRS1* (Gly/Arg) have significantly higher risk of OSA and NAFLD.

Several cross-sectional studies examined levels of liver enzymes in patients with OSA (19-23). Chin *et al.* (20) reported that elevated fasting AST levels in OSA patients and correlated with insulin resistance. Another study, Norman *et al.* (21) showed that ALT and AST levels were directly correlated with the severity of nocturnal hypoxia. Increased levels of ALT, AST and AP have been indicated in patients with moderate and severe OSA (22). Sing *et al.* (23) found OSA was prevalent in 46% of patients with higher AST levels. Similarly, the presence of severe OSA (AHI > 50/ minute) is an independent predictor of elevated liver enzymes (24). Based on these studies, an interesting finding in our study indicates that metabolic and liver markers are significantly higher in OSA with NAFLD patients.

From developed countries, a limited number of studies related to *IRS1* and *IRS2* gene polymorphisms focused on T2DM, OSA and NAFLD separately, but no study has been investigated the polymorphism in patients with OSA and NAFLD both. Li *et al.* (25) have shown that *IRS1* gene plays an important role in T2DM risk, especially in Asian. It also indicates that *IRS1* gene polymorphism is associated with T2DM risk in Caucasian. Another study, Dongiovanni *et al.* (9) reported that *IRS1* (Gly972Arg) polymorphism affects insulin receptor activity and predisposes to liver damage and decreases hepatic insulin signaling in patients with NAFLD. Li *et al.* (26) recruited 130 patients with obstructive sleep apnea hypopnea syndrome (OSAHS) and 136 age and gender matched healthy controls. He showed allele and genotype frequencies of *IRS1* gene showed significant differences between OSAHS and controls in the Chinese Han population. Our study also showed significant association of the *IRS1* (Gly/Arg) gene with OSA and NAFLD. Further, in a study from turkey on 972 OSA subjects, the polymorphism of the *IRS1* (Gly/Arg) was associated with the occurrence of OSAS in male patients, whereas this polymorphism was not related to the severity of OSAS (27), which was inconsistent with our finding. The discrepancy between our results and the previous result could be attributed to ethnicity, environmental factors and probably due to larger sample size of our study compared to previous study.

Insulin resistance is the key factor in NAFLD and OSA pathophysiology as well as in the progression of the disease. *IRS1* and *IRS2* are important for the development of NAFLD in the presence of insulin resistance. Insulin resistance signaling is an exclusively mediated by *IRS1* and *IRS2* in the liver (28). In this context, Mkaem *et al.* (29) suggested that *IRS1* Arg972 alleles are more prevalent in insulin-resistant subjects, and these alleles are also prevalent in overweight/ obese individuals. Another study reported that the effect of *IRS1* polymorphism on hepatic insulin resistance and he showed decreased hepatic levels, reflecting reduced insulin signaling activity (30). Interestingly, our study also indicated that *IRS1* polymorphism is significant genetic determinant for insulin resistance in OSA and NAFLD.

In the Pima Indians, the frequency of *IRS2* gene polymorphism is the highest compared to other populations (31). This may be because of the high prevalence of obesity and T2DM in the population. Additionally, the current research we did not find any association of *IRS2* gene with OSA and NAFLD patients. We believe that the *IRS2* (Gly1057Asp) polymorphism influence glucose homeostasis and obesity. A molecular mechanism related to *IRS2* polymorphism is still unknown. Based on these observations, it seems reasonable to speculate that *IRS-2* variants are not involved in the development of OSA and NAFLD.

Limitations of our study include samples are originated from north India. There is also the lack of data on siblings and other ancestral members of the recruited subjects, which could help in determining the effect of population stratification. Another limitation of our study is the lack of biopsy data and other ancestral members of the recruited subjects, which could help in determining expression across populations for the effect of population stratification. Further, although ultrasonography is a practical approach commonly used to detect liver steatosis, it is not the gold standard technique for quantitative liver fat assessment. Further, ultrasonography is the most common procedure for diagnosis of NAFLD in clinical practice and has a fair sensitivity (87%) and specificity (94%) in detecting hepatic steatosis (32). It is simple to perform, non-invasive, cost-effective and does not entail any radiation hazard, and could also be used in the epidemiological studies.

Conclusion

Genetic factors may predispose to OSA and NAFLD. We observed significant association of the *IRS1* (Gly/Arg) gene with OSA and NAFLD, whereas *IRS2* (Gly1057Asp) polymorphism is not related to the severity of OSA and NAFLD. Further, *IRS1* polymorphism is a significant genetic determinant for insulin resistance in OSA and NAFLD.

Abbreviations: OSA, Obstructive sleep apnea; NAFLD, non alcoholic fatty liver disease; T2DM, type 2 diabetes mellitus; CVD, cardio vascular disease; WC, waist circumference; HC, hip circumference; MTC, mid thigh circumference; FBG, fasting blood glucose; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase ; HOMA, homoeostasis modal assessment; PSG, polysomnography; AHI, *apnea-hypopnea index*.

Conflict of interest: None of the authors have any conflicts to disclose.

Financial Disclosure: This work was supported by a grant from the Ministry of Science and Technology, Department of Science and Technology (Ref: SR/SO/HS-0146/2010), Government of India. The funding agency had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements: The authors acknowledge the contribution of Mr Kirti Pratap who performed many of the biochemical investigations. Finally, the cooperation of the subjects who took part in the study is greatly appreciated.

Author Contribution: Bhatt SP; Data collection, anthropometry, biochemical, data analysis and wrote the manuscript and edited the manuscript. Guleria R; Investigator and contributed to the discussion.

References

1. Tufik S, R Santos-Silva, JA Taddei, LRA Bittencourt. 2010. Obstructive sleep apnea syndrome in the Sao Paulo epidemiologic sleep study. *Sleep Med*,11(5): 441e6.
2. Reddy EV, T Kadiravan, HK Mishra, V Sreenivas, KK Handa, S Sinha, et al. 2009. Prevalence and risk factors of obstructive sleep apnea among middle-aged urban Indians: a community-based study. *Sleep Med*, 10(8): 913e8.
3. Sharma SK, G Ahluwalia. 2010. Epidemiology of adult obstructive sleep apnea syndrome in India. *Indian J Med Res*. 131: 171-5.
4. Younossi ZM, AB Koenig, D Abdelatif, Y Fazel, L Henry, M Wymer. 2016. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*. 64(1): 73-84.
5. Bajaj S, A Nigam, A Luthra, RM Pandey, D Kondal, SP Bhatt, et al. 2009. A case-control study on insulin resistance, metabolic co-variables & prediction score in non-alcoholic fatty liver disease. *Indian J Med Res*. 129:285-92
6. Jin S, Jiang S, Hu A. Association between obstructive sleep apnea and non-alcoholic fatty liver disease: a systematic review and meta-analysis. *Sleep Breath*. 2018. Jan 15. doi: 10.1007/s11325-018-1625-7.
7. Mirrakhimov AE, VY Polotsky. 2012. Obstructive sleep apnea, and non-alcoholic Fatty liver disease: is the liver another target? *Front Neurol*. 17; 3(): 149.
8. Bayazit YA, ME Erdal, M Yilmaz, TU Ciftci, F Soyleme Z, T Gokdoğan, O Kokturk, YK Kemaloglu, A Koybasioglu. 2006. Insulin receptor substrate gene polymorphism is associated with obstructive sleep apnea syndrome in men. *Laryngoscope*. 116(11): 1962-5.
9. Dongiovanni P, L Valenti, R Rametta, AK Daly, V Nobili, E Mozzi, et al. 2010. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. *Gut*. 59(2): 267
10. Villuendas G, JI Botella-Carretero, B Roldán, J Sancho, HF Escobar-Morreale, JL San Millán. 2005. Polymorphisms in the insulin receptor substrate-1 (IRS-1) gene and the insulin receptor substrate-2 (IRS-2) gene influence glucose homeostasis and body mass index in women with polycystic ovary syndrome and non-hyperandrogenic controls. *Hum Reprod*. 20(11): 3184-91
11. Dudeja V, A Misra, RM Pandey, et al. 2001. BMI does not accurately predict overweight in Asian Indians in Northern India. *Br J Nutr*. 86: 105-112.
12. Bhatt SP, P Nigam, A Misra, R Guleria. 2013. Independent associations of low 25 hydroxy vitamin D and high parathyroid hormonal levels with non alcoholic fatty liver disease in Asian Indians residing in north India. *Atherosclerosis*, 230(1): 157-63.
13. Lambert M, G Paradis, J O'Loughlin, EE Delvin, JA Hanley, E Levy. 2004. Insulin resistance syndrome in a representative sample of children and adolescents from Quebec, Canada. *Int J Obes Relat Metab Disord*, 28: 833-841.
14. Matthews DR, JP Hosker, AS Rudenski, et al. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*. 28: 412-419.
15. Tam KM, JS Wu. 1986. Ultrasonographic diagnosis of fatty liver. *Taiwan Yi Xue Hui Za Zhi*. 85:45-53.
16. BaHammam AS, A Obeidat, K Barataman, SA Bahammam, AH Olaish, MM Sharif. 2014. A comparison between the AASM 2012 and 2007 definitions for detecting hypopnea. *Sleep Breath*. 18(4): 767-73.

17. Bhushan B, R Guleria, A Misra, RM Pandey, K Luthra, NK Vikram. 2009. Obstructive sleep apnoea correlates with C-reactive protein in obese Asian Indians. *Nutr Metab Cardiovasc Dis.* 19:184–9.
18. Shih-Hung Chan, Chen Jyh-Hong, Li Yi-Heng, and Tsai Liang-Miin. 2012. Gly1057Asp polymorphism of insulin receptor substrate-2 is associated with coronary artery disease in the Taiwanese population. *J Biomed Sci.* 19(1): 100.
19. Hilal Arikoglu, Hepdogru Aksoy Melda, K.E. Dudu, Asik Aycan, Ipekci Hilmi Suleyman, and Iscioglu Funda. 2014. IRS1 gene polymorphisms Gly972Arg and Ala513Pro are not associated with insulin resistance and type 2 diabetes risk in non-obese Turkish population. *Meta Gene.* 2014; 2: 579–585.
20. Chin, K., T. Nakamura, K. Takahashi, K. Sumi, Y. Ogawa, H. Masuzaki et al. 2003. Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients. *Am. J. Med.* 114, 370–376.
21. Norman, D., A W Bardwell, F. Arosemena, R. Nelesen, J P Mills, S. J Loreda et al. 2008. Serum aminotransferase levels are associated with markers of hypoxia in patients with obstructive sleep apnea. *Sleep*, 31. 121–126.
22. Shpirer, I. L. Copel, E. Broide, and A Elizur. 2010. Continuous positive airway pressure improves sleep apnea associated fatty liver. *Lung.* 188, 301–307.
23. Singh, H., R. Pollock, J. Uhanova, M. Kryger, K. Hawkins, and G. Y Minuk. 2005. Symptoms of obstructive sleep apnea in patients with nonalcoholic fatty liver disease. *Dig. Dis. Sci.* 50, 2338–2343.
24. Tanne, F., F Gagnadoux, O. Chazouilleres, B. Fleury,, D Wendum., E Lasnier., et al. 2005. Chronic liver injury during obstructive sleep apnea. *Hepatology.* 41, 1290–1296.
25. Li Q, Y Qiao, C Wang, G Zhang, X, Xu L Zhang. 2016. Associations between two single-nucleotide polymorphisms (rs1801278 and rs2943641) of insulin receptor substrate 1 gene and type 2 diabetes susceptibility: a meta-analysis. *Endocrine.* 51(1): 52-62.
26. Li Z, Tang T, Du J, Wu W, Zhou X, Qin G. 2016. Association between Single Nucleotide Polymorphisms in Gamma Aminobutyric Acid B Receptor, Insulin Receptor Substrate-1, and Hypocretin Neuropeptide Precursor Genes and Susceptibility to Obstructive Sleep Apnea Hypopnea Syndrome in a Chinese Han Population. *Med Princ Pract.* 25(6):517-524.
27. Bayazit YA, Yilmaz M, Kokturk O, et al. 2007. Association of GABA(B)R1 receptor gene polymorphism with obstructive sleep apnea syndrome. *ORL J Otorhinolaryngol Relat Spec.* 69:190–197.
28. Kubota, N. et al. 2008. Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signalling during fasting and feeding. *Cell Metab.* 8, 49–64.
29. Mkadem SA, C Lautier, F Macari, N Molinari, P Lefebvre, E Renard, et al. 2001. Role of allelic variants Gly972Arg of IRS-1 and Gly1057Asp of IRS-2 in moderate-to-severe insulin resistance of women with polycystic ovary syndrome. *Diabetes.* 50, 2164–2168.
30. Valenti L, R Rametta, P Dongiovanni, et al. 2008. Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. *Diabetes* ;57:1355e62
31. Fritsche A, A Madaus, W Renn, O Tschritter, A Teigeler, M Weisser, et al. 2001. The prevalent Gly1057Asp polymorphism in the insulin receptor substrate-2 gene is not associated with impaired insulin secretion. *J Clin Endocrinol Metab.* 86: 4822-4825.

32. Mathiesen UL, Franzen LE, Aselius H, Resjo M, Jacobsson L, Foberg U, Fryden A, et al. 2002. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis. 34:516-52.

Figure legend

Figure 1: Association of insulin receptor substrate -1 with clinical, body composition and biochemical parameters in obstructive sleep apnea and non-alcoholic fatty liver disease subjects. Values are presented in Mean and SD. P values<0.05 is statistically significant. BMI, body mass index; FFM, fat free mass; FBG, fasting blood glucose; TG, triglyceride; TC, total cholesterol; ALP, Alkaline phosphate; ALT, alanine transaminase; AST, aspartate transaminase; HOMA-IR, homoeostasis Model Assessment of insulin resistance.

Table 1: Clinical and body composition investigations

Variables	OSA with NAFLD (n=130)	OSA without NAFLD (n=100)	Without OSA and with NAFLD (n=95)	Without OSA and without NAFLD (n=85)	Overall P value
Systolic blood pressure (mmHg)	131.4±11.5 [¶]	130.2±15.6 [@]	126±20.6 [#]	120±16.9	0.001
Diastolic blood pressure (mmHg)	84.4±14.4 [¶]	83.5±13.6 [@]	82.2±15.4	80.1±13.6	0.003
Pulse Rate (minutes)	79.7±7.8	79.71±5.9	76.6±5.1	76.83±4.6	0.11
Body mass index (Kg/m ²)	33.3±7.9 [¶]	32.5±6.9 [@]	31.0±8.3 [#]	28.5±8.6	0.003
Fat mass (kg)	40.45±17.4 [*]	35.6±14.2	31.1±14	30.5±9.5	0.02
Fat free mass (kg)	54.1±12.1 [*]	52.4±11.7 [@]	48.03±12.1	45.7±9.7	0.002
Total body water (kg)	40.6±8.6	38.2±9.6	35.2±8.7	33.2±8.3	0.5
Body fat (%)	40.2±13.6 ^{¶ †}	38.2±11.6 [@]	37.1±12.8 [#]	34.6±11.6	0.002

Results are shown as mean± SD. P value ≤0.05 is statistically significant. *Group 1 vs 2, 1 vs 3 and 1 vs 4 (p≤0.05); # group 3 vs 4 (p≤0.05); @ group 2 vs 4 (p≤0.05); ¶ group 1 vs 4 (p≤0.05); †group 2 vs 3 (p≤0.05); ‡ group 1 vs 3 (p≤0.05).

Table 2. Anthropometry Parameters

Variables	OSA with NAFLD (n=130)	OSA without NAFLD (n=100)	Without OSA and with NAFLD (n=95)	Without OSA and without NAFLD (n=85)	Overall P value
Circumferences (cm)					
Waist	106.9±13.3 [‡]	104.2±14.6 [@]	102±13.5	100±15.6	0.001
Hip	109.5±13.2 [*]	106.5±23.5 [@]	103±16.9 [#]	101.7±15.9	0.003
Mid thigh	55.8±7.4 [¶]	54.1±8.6	53.2±8.9	52±7.9	0.005
Mid Arm	32.16±7.6 [¶]	30±6.5	29.7±6.4	24.6±5.6	0.6
Neck	38.74±5.6 [¶]	38.3±3.6	36.2±4.04	32.1±3.1	0.0004
Skinfold thickness (mm)					
Biceps	16.8±7.07	15.4±6.7	17.36±5.4	15.2±5.5	0.9
Triceps	25.0±10.5	24.3±9.3	24.3±7.7	22.2±9.3	0.44
Subscapular	30±8.1	29.2±9.8	27±5.6	26±6.5	0.2
Antaxillary	17±6.0	14.6±5.3	13.27±5.2	13.7±5.1	0.5
Suprailiac	31.8±9.8 [*]	29.2±10.5	28.1±9.5	27±8.9	0.02
Lateral thoracic	33.7±11.1 [¶]	31.9±12.5	30.1±11.9	28.9±9.8	0.02
Thigh	30.1±11.3 [‡]	26±9.9	25.4±6.6	24.7±8.1	0.05

Results are shown as mean± SD. P value ≤0.05 is statistically significant. *Group 1 vs 2, 1 vs 3 and 1 vs 4 (p≤0.05); [¶] group 1 vs 4 (p≤0.05); [‡] group 1 vs 3 (p≤0.05); [@] group 2 vs 4 (p≤0.05); [#] group 3 vs 4 (p≤0.05).

Table 3: Biochemical Investigations

Variables	OSA with NAFLD (n=130)	OSA without NAFLD (n=100)	Without OSA with NAFLD (n=95)	Without OSA and without NAFLD (n=85)	Overall P value
Fasting Blood Glucose (mg/dl)	103±25.2 ^{¶, ‡}	104.1±38.4 [‡]	98.14±21.2	90.3±24.4	0.004
Serum Triglycerides (mg/dl)	189±40.6 [*]	177±46.9 [@]	158.1±55.2 [#]	151±58.9	0.01
Total Cholesterol (mg/dl)	185±38.3 [*]	180±44.6 [@]	178±43.6 [#]	171±39.8	0.02
High density lipoprotein (mg/dl)	42.4±8.3 [¶]	43.8±11.7	44.6±9.1 [#]	52.3±10.2	0.005
Low density lipoprotein	112.6±40.2 [¶]	109±36.5 [@]	109±35.6 [#]	98±30.8	0.002
Very low density lipoprotein	33.5±11.2	32±12.3	31±11.3	30.0±9.6	0.4
Aspartate transaminase (IU/L)	44.5±15.9 ^{¶, ‡}	41.4±22.1 [‡]	39.6±19.6 [#]	31.6±15.9	0.01
Alanine transaminase (IU/L)	60.9±10.3 [*]	54.2±12.9 [@]	52.3±11.9	50.9±10.9	0.03
Alkaline phosphate (IU/L)	240.6±74.3 ^{¶, ‡}	242±76.5	235±72.9	235±69.8	0.05
Fasting Insulin (μU/ml)	12±4.3 [*]	11.1±4.8 [‡]	9.3±3.6	9.3±3.8	0.001
HOMA-IR	2.9±0.92 [*]	2.5±0.98 [@]	1.9±0.86	1.6±0.76	0.001

Results are shown as mean± SD. P value ≤0.05 is statistically significant. *Group 1 vs 2, 1 vs 3 and 1 vs 4 (p≤0.05); ‡group 2 vs 3 and group 2 vs 4 (p≤0.05); # group 3 vs 4 (p≤0.05); @ group 2 vs 4 (p≤0.05); ¶ group 1 vs 4 (p≤0.05); ‡ group 1 vs 3 (p≤0.05). HOMA-IR, homoeostasis modal assessment for insulin resistance.

479

480 Table 4. Allele distribution of IRS1 and IRS2 genes polymorphisms between the groups.

	OSA with NAFLD (N=130)	OSA without NAFLD (N=100)	Without OSA with NAFLD (N=95)	Without OSA and without NAFLD (N=85)	P ^a	Odds ratio (95% CI)	P ^b	
IRS1 [Gly972Arg, n(%)]								
Allele Gly	112 (86.5)	89 (89)	86 (90.5)	79 (93)	0.04	1 (refrence)	0.002	
Allele Arg	18 (13.5)	11 (11)	9 (9.5)	6 (7)		2.25 (1.41-3.30)		
Additive model							4.04 (1.52-11.51)	0.001
IRS2 [Gly1057Asp, n ((%)]								
Allele Gly	118 (91)	92 (92)	88 (93)	82 (96.5)	0.06	1 (refrence)	0.08	
Allele Asp	12 (9)	8 (8)	7 (7)	3 (3.5)		0.98 (0.75-1.99)		
Additive model							1.10 (0.8-2.56)	0.06

481

482

483

484

485

486

487

488

489

490

491

492

493

494 Results are shown as n (%). P value ≤ 0.05 is statistically significant.

495 ^aP value was computed by the pearson chi-square test

496 ^bData were calculated by logistic regression after adjusting for age, body mass index, fat mass, % body fat, fasting blood
497 glucose, serum triglyceride, total cholesterol and fasting insulin.

498

499

Figure